CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients ...

ChristianaCare’s Gene Editing Institute has secured a prominent place on The Scientist’s Top 10 Innovations list for 2024, ...

The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

The legacy of our ancient human relatives, "brain-eating-amoeba" infections, emerging viral threats, the promise and peril of ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Within the human digestive tract are trillions of bacteria from thousands of different species. These bacteria form ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day. We recently compiled a list of the Top 11 CRISPR ...